Bayer Schering Pharma starts Phase III studies with low-dose contraceptive patch

Published: 5-May-2009
Regulatory Research & Development

Bayer Schering Pharma of Germany is starting Phase III trials with a patch for female contraception that combines low dosed ethinylestradiol and gestodene. This month approximately 3,300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch. Bayer plans to submit the new patch for registration worldwide, with the first filing expected in 2012.


Bayer Schering Pharma of Germany is starting Phase III trials with a patch for female contraception that combines low dosed ethinylestradiol and gestodene. This month approximately 3,300 women will be enrolled into two global studies to evaluate the contraceptive reliability of the patch. Bayer plans to submit the new patch for registration worldwide, with the first filing expected in 2012.

"Bayer Schering Pharma is looking forward to progressing to Phase III trials with our novel patch. It will be the smallest, lowest dosed and the only transparent patch for female contraception on the market," said Phil Smits, head of women's healthcare at Bayer Schering Pharma. "We are optimistic that these attributes will make it an attractive option for women seeking alternative routes of hormonal contraception."

The patch will be applied once a week, i.e. three patches per cycle (for 21 days), then one week off. Bayer says the simple handling will make the product convenient to use, and therefore, a good compliance from the user is anticipated.

See more

You may also like

Research & Development

LIfT BioSciences licenses Bayer's Cambridge lab facilities to advance oncology research

Read more
LIfT will use Bayer's Co.Lab facilities to advance its immuno-modulatory alpha neutrophil platform for the mitigation of treatment resistance in solid tumours

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

LIfT BioSciences licenses Bayer's Cambridge lab facilities to advance oncology research

LIfT will use Bayer's Co.Lab facilities to advance its immuno-modulatory alpha neutrophil platform for the mitigation of treatment resistance in solid tumours
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Research & Development

Recursion adds new chemical entity targeting fibrotic diseases to late discovery pipeline

Potential first-in-class molecule with novel target inlicensed from collaboration with Bayer
Regulatory

Pistoia Alliance announces data management toolkit

Roche, AstraZeneca and Bayer supports FAIR Implementation project to improve data management and better AI and machine learning for the "Lab of the Future"
Design & Build

Bayer chooses Fluor and GE Healthcare for new cell culture technology centre

Company will invest US$150 million in new California facility expected to be ready for clinical production in late 2021
Ingredients

Therapeutics: anticancer agent: larotrectinib

TRK (tropomyosin receptor kinase) fusion cancers occur when an NTRK gene fuses with another, unrelated gene, leading to the formation of an altered TRK protein
Ingredients

Therapeutics: darolutamide for prostate cancer

Prostate cancer is the second most commonly diagnosed cancer in men and leads to the fifth highest number of male cancer deaths
Subscribe now